Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Change in Accured Expenses (2019 - 2026)

Enliven Therapeutics has reported Change in Accured Expenses over the past 8 years, most recently at -$4.5 million for Q1 2026.

  • Quarterly results put Change in Accured Expenses at -$4.5 million for Q1 2026, down 78.96% from a year ago — trailing twelve months through Mar 2026 was -$2.5 million (down 865.84% YoY), and the annual figure for FY2025 was -$496000.0, down 100.0%.
  • Change in Accured Expenses reached -$4.5 million in Q1 2026 per ELVN's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.8 million in Q4 2023 and bottomed at -$4.5 million in Q1 2026.
  • Median Change in Accured Expenses over the past 5 years was $387000.0 (2022), compared with a mean of $239294.1.
  • Peak annual rise in Change in Accured Expenses hit 1098.19% in 2023, while the deepest fall reached 897.2% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $663000.0 in 2022, then soared by 621.27% to $4.8 million in 2023, then plummeted by 126.85% to -$1.3 million in 2024, then skyrocketed by 191.59% to $1.2 million in 2025, then plummeted by 479.68% to -$4.5 million in 2026.
  • Business Quant data shows Change in Accured Expenses for ELVN at -$4.5 million in Q1 2026, $1.2 million in Q4 2025, and $814000.0 in Q3 2025.